Humacyte Analyst Price Targets - Benzinga

Humacyte Inc

HUMANASDAQ

Trade with Public

Trade with Public

$0.4006

-0.0348-7.99%

Ult. Agg.: Oct 27, 6:25 AM

Panoramica Notizie Previsioni utili EventiObiettivi di prezzoDati finanziari Sentiment Azionariato Confronta Rapporto azionario

Humacyte Analyst Price Targets

Wall Street analyst price targets and consensus rating for Humacyte (HUMA).

Price Target Range — 13 Quarters

Analyst Consensus — 7 Analysts

6Buy

1Hold

Consensus RatingBuy# Analysts7Avg. Consensus PT$5Upside to Avg. PT+1116.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 7, 2026	Barclays	Christopher Pasquale	Initiate	Equal-Weight	$1
Aug 13, 2026	Benchmark	Bruce D. Jackson	PT Cut	Speculative Buy	$2→$1
Jul 28, 2026	BTIG	Ryan Zimmerman	Maintained	Buy	$2
Jun 17, 2026	TD Cowen	Joshua Jennings	PT Cut	Buy	$2→$1
Jun 16, 2026	BTIG	Ryan Zimmerman	Maintained	Buy	$2
Jun 11, 2026	HC Wainwright & Co.	Swayampakula Ramakanth	PT Raise	Buy	$3→$4
Jun 8, 2026	BTIG	Ryan Zimmerman	Maintained	Buy	$2
Jun 1, 2026	Benchmark	Bruce D. Jackson	PT Raise	Speculative Buy	$1→$2
May 26, 2026	HC Wainwright & Co.	Swayampakula Ramakanth	Maintained	Buy	$3
May 14, 2026	TD Cowen	Joshua Jennings	PT Raise	Buy	$1→$2
May 13, 2026	BTIG	Ryan Zimmerman	PT Cut	Buy	$3→$2
Apr 28, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$25
Apr 28, 2026	BTIG	Ryan Zimmerman	Maintained	Buy	$3
Apr 24, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$25
Apr 21, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$25
Apr 8, 2026	Barclays	Matt Miksic	PT Cut	Overweight	$4→$2
Mar 31, 2026	Benchmark	Bruce D. Jackson	Downgrade	Buy→Speculative Buy	$10→$1
Mar 30, 2026	Piper Sandler	Allison Bratzel	PT Cut	Neutral	$3→$1
Mar 30, 2026	TD Cowen	Joshua Jennings	PT Cut	Buy	$4→$1
Mar 27, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$25

Analyst Ratings News

PRO
Barclays Initiates Coverage On Humacyte with Equal-Weight Rating, Announces Price Target of $0.5

Barclays analyst Christopher Pasquale initiates coverage on Humacyte (NASDAQ:HUMA) with a Equal-Weight rating and announces Price Target of $0.5.

Benzinga Newsdesk

PRO
Benchmark Maintains Speculative Buy on Humacyte, Lowers Price Target to $1

Benchmark analyst Bruce D. Jackson maintains Humacyte (NASDAQ:HUMA) with a Speculative Buy and lowers the price target from $2 to $1.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Humacyte, Maintains $2 Price Target

BTIG analyst Ryan Zimmerman reiterates Humacyte (NASDAQ:HUMA) with a Buy and maintains $2 price target.

Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on Humacyte, Lowers Price Target to $1.25

TD Cowen analyst Joshua Jennings maintains Humacyte (NASDAQ:HUMA) with a Buy and lowers the price target from $1.5 to $1.25.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Humacyte, Maintains $2 Price Target

BTIG analyst Ryan Zimmerman reiterates Humacyte (NASDAQ:HUMA) with a Buy and maintains $2 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Humacyte, Raises Price Target to $4

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Humacyte (NASDAQ:HUMA) with a Buy and raises the price target from $3 to $4.

Benzinga Newsdesk